Autor: |
Burc E. Sahin, Asuman Celikbilek, Yusuf Kocak, Bilal Ilanbey, Gamze T. Saltoglu, Naime M. Konar, Lokman Hizmali |
Přispěvatelé: |
Tıp Fakültesi, Burç Esra Şahin/ 0000-0003-1008-2743, Asuman Çelikbilek / 0000-0002-2367-1128, Yusuf Koçak / 0000-0003-4511-1321, Bilal İlanbey / 0000-0002-7614-281X, Naime Meriç Konar / 0000-0002-6593-7617, Lokman Hızmalı / 0000-0001-9548-3030 |
Jazyk: |
angličtina |
Rok vydání: |
2023 |
Předmět: |
|
Popis: |
A wide spectrum of neurological symptoms (NS) has been described in patients with COVID-19. We examined the plasma levels of neuron-specific enolase (NSE) and neurofilament light chain (NFL) together, as neuronal damage markers, and their relationships with clinical severity in patients with NS at acute COVID-19. A total of 20 healthy controls and 59 patients with confirmed COVID-19 were enrolled in this pilot prospective study. Serum NSE and NFL levels were measured by using the enzyme-linked immunoassay method from serum samples. Serum NSE levels were found to be significantly higher in the severe group than in the nonsevere group (p = 0.034). However, serum NFL levels were similar between the control and disease groups (p > 0.05). For the mild group, serum NFL levels were significantly higher in patients with the sampling time >= 5 days than in those with the sampling time 0.05). Increased serum NSE levels were associated with disease severity regardless of accompanied NS in patients with acute COVID-19 infection. However, serum NFL levels may have a role at the subacute phase of COVID-19. |
Databáze: |
OpenAIRE |
Externí odkaz: |
|